Collaboration and license agreements - Schedule of financial information related to collaboration and license agreements (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	$ 11,799	$ 1,473
Deferred revenue, current	15,471	16,618
Deferred revenue, net of current	21,814	16,895
Deferred Revenue, Total	37,285	33,513
Roche Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	0	417
Deferred revenue, current	2,667	4,649
Deferred revenue, net of current	11,814	16,895
Deferred Revenue, Total	14,481	21,544
Betta Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	1,799
Deferred revenue, current	4,000
Deferred revenue, net of current	8,000
Deferred Revenue, Total	12,000
Merck Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	10,000
Deferred revenue, current	8,000
Deferred revenue, net of current	2,000
Deferred Revenue, Total	10,000
Biogen Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable	0	0
Deferred revenue, current	804	11,427
Deferred revenue, net of current	0	0
Deferred Revenue, Total	$ 804	11,427
Calico Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable		1,056
Deferred revenue, current		542
Deferred revenue, net of current		0
Deferred Revenue, Total		$ 542